In addition, CD56dim NK cells from TKI-treated CML patients have higher expression of CD57, a marker of highly differentiated NK cells (22, 30), and NKp44 indicating that NK cells from TKI-treated CML patients are highly differentiated activated NK cells, as it has been recently suggested (40, 54). The gene discussed is B3GAT1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.